### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **BMID 9809 US** 

Total Pages in this Submission 53

### TO THE ASSISTANT COMMISSIONER FOR PATENTS

**Box Patent Application** Washington, D.C. 20231

Tı in

bolitica antitlad	ewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application f	36
ENZYME/TA	AG BINDING AND DETECTION SYSTEM	310
and invented by:		
DWULET, F	rancis Edward; BALGOBIN, Neil Gwyn; and McCARTHY, Robert Crane	
If a CONTINUA	ATION APPLICATION, check appropriate box and supply the requisite information:	
Continuat		
Which is a:	Continuation-in-part (CIP) of prior application No.:	
- Continuat	tion   Divisional   Continuation-in-part (CIP) of prior application No.:	
Which is a:	tion Divisional Continuation-in-part (CIP) of prior application No.:	
୍⊟ Continua	tion Divisional Continuation-in-part (CIP) of prior application 1988	
Enclosed are:		
Enclosed are.	Application Elements	
lasa 1. ⊠ Fili	ing fee as calculated and transmitted as described below	
### (### ### ### ### ### ### ### ### ##	rance and including the following:	
2. 🗵 Sp	pecification having30 pages and including the following.	
a. 🗵	Descriptive Title of the Invention	
b. 🗆	Cross References to Related Applications (if applicable)	
c. 🗆	Parasting Fodorally-sponsored Research/Development (if applicable)	
d. 🗆	Reference to Microfiche Appendix (if applicable)	
e. 🗵	and the state of	
f. 🗵	and the state of t	
l l	Devices (if drowings filed)	
g. 🗆		
h. 🗵		
i. 🗵		
j. <u>Σ</u>	Abstract of the Disclosure	

### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. **BMID 9809 US** 

Total Pages in this Submission 53

Application Elements (Continued)	
3. Drawing(s) (when necessary as prescribed by 35 USC 113)	
a.  Formal Number of Sheets	
b. 🔲 Informal Number of Sheets	
4. 🗵 Oath or Declaration	
a 🕅 Newly executed (original or copy) 🔲 Unexecuted	
b.   Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)	
c. 🗵 With Power of Attorney 🔲 Without Power of Attorney	
d. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. 1.63(d)(2) and 1.33(b).	
5. Incorporation By Reference (usable if Box 4b is checked)  The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	
6. Computer Program in Microfiche (Appendix)	
7. 🗵 Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)	
a. 🗵 Paper Copy	
b. 🗵 Computer Readable Copy (identical to computer copy)	
c. Statement Verifying Identical Paper and Computer Readable Copy	
Accompanying Application Parts	
8. Assignment Papers (cover sheet & document(s))	١
9. 🔲 37 CFR 3.73(B) Statement (when there is an assignee)	
10. 🔲 English Translation Document (if applicable)	
11.  ☐ Information Disclosure Statement/PTO-1449 ☐ Copies of IDS Citations	
12. 🔲 Preliminary Amendment	
13. 🗵 Acknowledgment postcard	
14.   Certificate of Mailing	
☐ First Class ☒ Express Mail (Specify Label No.): EL 841984005 US	

### UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No. BMID 9809 US

Total Pages in this Submission

	Accompanying Application Parts (Continued)
5. 🗆	Certified Copy of Priority Document(s) (if foreign priority is claimed)
	Additional Enclosures (please identify below):
6. 🗆	Additional Environment
	Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)
47. 🗖	Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in published pur
	Warning
	An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, within the prescribed period shall result in the application being regarded as abandoned, within the satisfaction of the Director that the delay in submitting the notice was unintentional.

# UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
BMID 9809 US

Total Pages in this Submission 53

### Fee Calculation and Transmittal

		CLAIMS				Fee
	#Filed	#Allowed	#Extra	Rate		
For		- 20 =	0	x \$18.00		\$0.0
otal Claims	10	- 20 -		x \$80.00		\$0.0
dep. Claims	3	- 3 =	0	x \$80.00		\$0.0
ultiple Dependent (	Claims (check	( if applicable)			BASIC FEE	\$710.
						\$0.
OTHER FEE (speci	fy purpose)			TOTA	AL FILING FEE	\$710
<ul><li>☐ A check in the ar</li><li>☑ The Commission as described be</li></ul>	nor is hereby a	authorized to cha	rge and credit	ing fee is enclosed. Deposit Account No	02-2958	

CC:

Serial No. Filling Date	CERTIFICATE OF MA		MAIL" (37 CFR 1.10)	Docket No.  BMID9809US			
I hereby certify that this  U.S. Utility Patent Application (Identify type of correspondence)  is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 of July 10, 2001.  (Date)  Rose Edwards  (Typed or Printed Name of Person Mailing Correspondence)  (Signature of Person Mailing Correspondence)  EL 841984005 US		_		Group Art Unit  To Be Assigned			
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 of July 10, 2001.    Rose Edwards   Rose Edwards   CTyped or Printed Name of Person Mailing Correspondence)	ention: ENZYME/TAG	BINDING AND DETECTION					
37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231 of July 10, 2001.  (Date)  Rose Edwards  (Typed or Printed Name of Person Mailing Correspondence)  Pal Addada  (Signature of Person Mailing Correspondence)  EL 841984005 US	I hereby certify that this		<u>U.S. Utility Patent Application</u> (Identify type of correspondence)				
July 10, 2001.  (Date)  Rose Edwards  (Typed or Printed Name of Person Mailing Correspondence)  Par Edward  (Signature of Person Mailing Correspondence)  EL 841984005 US							
(Date)  Rose Edwards  (Typed or Printed Name of Person Mailing Correspondence)  Part Edwards  (Signature of Person Mailing Correspondence)  EL 841984005 US			tant Commissioner for Patents, W	ashington, D.C. 20231 on			
(Typed or Printed Name of Person Mailing Correspondence)  Parl Edwards—  (Signature of Person Mailing Correspondence)  EL 841984005 US							
PAIL EDWAND  (Signature of Person Mailing Correspondence)  EL 841984005 US							
EL 841984005 US	fru a c	(Typed or Printed Name of Person Mailing Correspondence)					
EL 841984005 US	er i		Pari Edi	wards-			
EL 841984005 US			(Signature of Person Mailing C	Correspondence)			
			-				
("Express Mail" Mailing Label Number)							
	2.00°		("Express Mail" Mailing L	abel Number)			

Note: Each paper must have its own certificate of mailing.

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dwulet et al.

Application No.: unknown

Group No.: unknown

Filed: July 10, 2001

Examiner: unknown

For: ENZYME/TAG BINDING AND DETECTION SYSTEM

Box SN Assistant Commissioner for Patents Washington, D.C. 20231

## STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Dear Sir:

The undersigned hereby states that the content of the Sequence Listing filed herewith (4 pages, numbered 1 to 4) and the computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same and contain no new matter. Also enclosed is a Checker 3.0 Verification Summary Report demonstrating that the Sequence Listing complies with the applicable rules.

Respectfully submitted,

Date: July 10, 2001

Kenneth J. Waite, Reg. No. 45,189 Roche Diagnostics Corporation 9115 Hague Road, Bldg. D

P.O. Box 50457

Indianapolis, IN 46250-0457 Telephone: (317) 521-3104